a study found that the Sinopharm vaccine is safe and generates a strong immune response in boys aged 3 to 17

According to the results of phase 1 and 2 trials of its development, Sinopharm’s anticovid-19 vaccine was shown to be safe and generated a “strong immune response after two doses ” in children aged 3 to 17. This was published by the prestigious scientific journal The Lancet Infectious Diseases.

Its effectiveness will only be evaluated in phase 3. However, Chinese scientists have reported that the formula, formally called BBIBP-CorV “It is safe and well tolerated”, and which “elicits strong humorous responses [generación de anticuerpos] against SARS-CoV-2 infection after two doses ”.

In the trial randomized, double-blind and controlled, phase 1 and 2, reported in the scientific journal The Lancet Infectious Diseases, it was carried out by stratifying healthy volunteers by age.

The researchers divided into three groups, which received different doses of vaccination:

• From three to five years old.
• Six to 12.
• From 13 to 17.

According to the researchers, the doses were administered with 28 days of separation. 445 boys participated in phase 1, while 810 children were selected for phase 2.

Regarding safety, scientists have assured that the undesirable effect the most common was the pain at the injection site, Followed by fever. In most cases, the severity of these effects “was mild to moderate” and they were “transient or resolved within days”.

“The inactivated covid-19 vaccine BBIBP-CorV is safe and well tolerated at all levels tested in participants aged 3 to 17 yearsThe scientists said and added: “The side effects occurred mainly after the first dose and showed a similar frequency to that seen in participants aged 18 to 59 and those aged 60 and over. “

Meanwhile, when evaluating its immunogenicity, that is, the ability of the serum to induce an immune response, they stated that it “causes strong humoral responses against infection by SARS-CoV-2 after two doses ”.

They noted that although the efficacy of the vaccine is still unknown, the serum-induced immune response in children aged three to 17 is similar to that expressed in adultsbecause “100% seroconversion was achieved in all participants on day 56”.

Regarding phase 3 of the study, scientists anticipated that for this age group will take place in the United Arab Emirates, where the vaccines will be administered “21 days apart to obtain additional data on safety, immunogenicity and efficacy.”

LGP